Table 3.
Impact of sex used for estimated glomerular filtration calculation in the population taking gender-affirming hormones.
| Estradiol cohort1 | eGFR category for CKD if male used for eGFR calculation2,3 | ||||||
|---|---|---|---|---|---|---|---|
|
eGFR category for CKD if female used for eGFR calculation2,3 |
1 | 2 | 3a | 3b | 4 | 5 | |
| 1 | 530 | ||||||
| 2 | 318 | 53 | |||||
| 3a | 61 | ||||||
| 3b | 15 | 1 | |||||
| 4 | 1 | ||||||
| 5 | 9 | 4 | |||||
| Testosterone cohort1 | eGFR category for CKD if male used for eGFR calculation2,3 | ||||||
| eGFR category for CKD if female used for eGFR calculation2,3 | 1 | 2 | 3a | 3b | 4 | 5 | |
| 1 | 345 | ||||||
| 2 | 99 | 20 | |||||
| 3a | 25 | ||||||
| 3b | 5 | 1 | |||||
| 4 | 2 | 1 | |||||
| 5 | 1 | ||||||
1The estradiol data consisted of 992 creatinine measurements on 406 unique patients 18 years and older taking estradiol as gender-affirming therapy. Observed agreement 0.59, weighted κ 0.40 (95 % CI 0.35–0.46).
2Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
3eGFR category for CKD: stage 1, normal or high (eGFR > 90 ml/min/173 m2); stage 2, mildly decreased (eGFR 60–89); stage 3a, mildly to moderately decreased (eGFR 45–59); stage 3b, moderately to severely decreased (eGFR 30–44); stage 4, severely decreased (eGFR 15–29); stage 5, kidney failure (eGFR < 15). eGFR was calculated using the CKD-EPI (2021) eGFR equation without race refit.
4The testosterone data consisted of 477 creatinine measurements on 214 unique patients 18 years and older taking testosterone as gender-affirming therapy. Observed agreement 0.74, weighted κ 0.46 (95 % CI 0.38–0.54).